CA2634923C — Acetylenic bicyclic heteroaryl compounds useful as kinase inhibitors
Assigned to Ariad Pharmaceuticals Inc · Expires 2015-05-05 · 11y expired
What this patent protects
The invention relates to acetylenic bicyclic heteroaryl compounds of the general formula (1) in which the variable groups are as defined herein, and to their preparation and use as protein kinase inhibitors and also in the treatment of cancer, bone disorders, metabolic disorders,…
USPTO Abstract
The invention relates to acetylenic bicyclic heteroaryl compounds of the general formula (1) in which the variable groups are as defined herein, and to their preparation and use as protein kinase inhibitors and also in the treatment of cancer, bone disorders, metabolic disorders, inflammatory disorders and other diseases. (see above formula)
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.